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Abstract
Background: Induction therapy can improve kidney transplantation (KTx) outcomes, but little is known about the
mechanisms underlying its effects.
Methods: The mRNA levels of T cell-related genes associated with tolerance or rejection (CD247, GZMB, PRF1,
FOXP3, MAN1A1, TCAIM, and TLR5) and lymphocyte subpopulations were monitored prospectively in the peripheral
blood of 60 kidney transplant recipients before and 7, 14, 21, 28, 60, 90 days, 6 months, and 12 months after KTx.
Patients were treated with calcineurin inhibitor-based triple immunosuppression and induction with rabbit anti-
thymocyte globulin (rATG, n = 24), basiliximab (n = 17), or without induction (no-induction, n = 19). A generalized
linear mixed model with gamma distribution for repeated measures, adjusted for rejection, recipient/donor age and
delayed graft function, was used for statistical analysis.
Results: rATG treatment caused an intense reduction in all T cell type population and natural killer (NK) cells within
7 days, then a slow increase and repopulation was observed. This was also noticed in the expression levels of
CD247, FOXP3, GZMB, and PRF1. The basiliximab group exhibited higher CD247, GZMB, FOXP3 and TCAIM mRNA
levels and regulatory T cell (Treg) counts than the no-induction group. The levels of MAN1A1 and TLR5 mRNA
expressions were increased, whereas TCAIM decreased in the rATG group as compared with those in the no-
induction group.
Conclusion: The rATG induction therapy was associated with decreased T and NK cell-related transcript levels and
with upregulation of two rejection-associated transcripts (MAN1A1 and TLR5) shortly after KTx. Basiliximab treatment
was associated with increased absolute number of Treg cells, and increased level of FOXP3 and TCAIM expression.
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Summary
In a prospective open study, rATG induction therapy was
associated with profound decreases of T and NK cell-
related transcripts and with the upregulation of two
rejection-associated transcripts (MAN1A1A and TLR5) in
the early post-KTx period. Basiliximab induction was
associated with increased absolute number of Treg cells,
and increased expression of tolerance associated markers
FOXP3 and TCAIM.
Background
Long-term allograft survival requires lifelong immuno-
suppression, the use of which could be accompanied by
several side effects [1]. For many patients triple drug
regimens are not necessary due to weak alloreactive
responses. Therefore, a development of reliable tests that
may help identify patients suitable for drug minimization
or at risk for rejection is needed. Several markers of
rejection or operational tolerance (defined as good and
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stable graft function in immunosuppression free pa-
tients) have been identified [2–8].
Granzyme B (GZMB) and perforin (PRF1) are effector
molecules produced by cytotoxic T and natural killer (NK)
cells. Perforin forms a pore in the target cell membrane
and thus facilitates the entry of granzyme B and other
compounds into the cell which subsequently leads to
apoptosis [9]. The urine and peripheral blood transcript
levels of PRF1 and GZMB were shown to be increased in
kidney transplant recipients with acute rejection [2, 3].
The ζ-chain of T cell receptor (CD247) is a part of T-cell
receptor-CD3 complex on T cells and activating receptors
on NK cells [10]. Transcription of CD247 was shown to
be downregulated in peripheral blood lymphocytes from
patients with long-term surviving kidneys [4, 10]. Toll-like
receptor 5 (TLR5) is a member of TLR family which plays
a fundamental role in the pathogen recognition and asso-
ciated activation of innate immunity. The expression of
TLR5 was downregulated in operationally tolerant kidney
graft recipients [5]. FoxP3 (forkhead box P3) is a key
transcription factor in CD4+CD25+FoxP3+ regulatory T
cells (Tregs), necessary for their differentiation and main-
tenance in the periphery [11]. Peripheral blood mRNA
levels of FOXP3 were higher in patients with operational
tolerance or stable kidney graft function compared to
patients with chronic rejection [7, 8]. A reduced gene-
expression ratio of FOXP3 to α-1,2-mannosidase
(MAN1A1) was observed for chronically rejecting patients
[5, 6]. Alpha-1,2-mannosidases (MAN1A1) are transmem-
brane proteins that specifically cleave α-1,2-linked man-
nose residues from oligosaccharides and are involved in
the synthesis and maturation of N-glycoproteins [12].
TCAIM (T cell activation inhibitor, mitochondrial; previ-
ously named TOAG-1) was highly expressed during the
induction and maintenance of tolerance, but was down-
regulated during acute rejection [6].
The induction therapy (with either lymphocyte-
depleting agents including rabbit anti-thymocyte globulin
(rATG) or IL-2 receptor antagonist such as basiliximab) is
recommended as part of the initial immunosuppressive
regimen in kidney transplant recipients to reduce acute
rejection and/or to allow the reduction of other compo-
nents of the regimen [13].
We and others previously demonstrated that induction
therapy with rATG was associated with the expansion of
relative numbers of CD4+CD25+FoxP3+ Treg during T cell
depletion [14, 15] and that basiliximab induction caused
the transient appearance and disappearance of CD4
+CD25low/-FoxP3+ and CD4+CD25+FoxP3+ Treg, respect-
ively [14, 16]. Furthermore we showed that high ratios of
CD4+FoxP3+ Tregs to effector T cells in peripheral blood
of kidney graft recipients treated with basiliximab induc-
tion in early post-transplant period were associated with
the absence of rejection [14].
However, little is known about the effect of rATG and
basiliximab on the expression of genes associated with
rejection or operational tolerance in clinical kidney trans-
plantation. Therefore, in order to address this issue, we
measured relative quantities of seven selected molecular
markers associated with rejection or tolerance (CD247,
GZMB, PRF1, MAN1A1, TLR5, FOXP3 and TCAIM) and
numbers of lymphocyte subpopulations (CD3+, CD4+,
CD8+, NK, CD4+FOXP3+) in the peripheral blood of




Between September 2009 and November 2010, 75 con-
secutive recipients of kidney transplants from deceased
donors were enrolled in a single-centre prospective study.
Written informed consent was obtained from all partici-
pants. The study protocol was approved by the Ethics
Committee of the Institute for Clinical and Experimental
Medicine (No. 608-08-10). Sixty patients met all of the
following inclusion criteria for the study: 1) sufficient
mRNA obtained during at least 7/9 sampling time-points,
2) unchanged maintenance immunosuppression, and 3)
no steroid-resistant rejection.
Patients were treated in accordance with the centre’s
immunosuppression treatment protocol which consisted of
triple maintenance therapy with a calcineurin inhibitor
(CNI; tacrolimus or cyclosporine A), mycophenolate mofe-
til, and corticosteroids. Patients were recruited for a specific
induction therapy on the basis of personal immunologic
risk factors. Patients with a panel-reactive antibody (PRA)
score ≥ 50 % or with previous renal transplantation received
1–1.5 mg/kg/day rATG (Thymoglobulin®, Genzyme Cor-
poration, Cambridge, MA, n = 24) in 2–7 doses during the
first week after KTx. Patients with PRA scores of 20–49 %
or the ones who received a kidney from an extended
criteria donor were treated with 20 mg of basiliximab
(Simulect®, Novartis, Basel, Switzerland, n = 17) on the day
of KTx and 4 days after. Patients with PRA score < 20 % re-
ceived no induction therapy (n = 19).
Peripheral blood samples were collected before and 7,
14, 21, 28, 60, 90 days, 6 months, and 12 months after
KTx. Except for differences in the retransplantation
frequency, mean PRA score, and donor age, the clinical
characteristics did not differ significantly among the
three groups (Table 1).
Histology and treatment of rejection
Kidney graft biopsies were performed on the basis of clin-
ical indications (case biopsies) or 90 days after KTx, as
defined by the protocol. Acute rejection was diagnosed
according to the Banff ’05 classification [17]. Borderline
changes and grade I or IIA T cell-mediated rejection were
Krepsova et al. BMC Nephrology  (2015) 16:146 Page 2 of 9
treated with 1.5–2 g of methylprednisolone. Antibody-
mediated rejection was treated by plasma exchange and
intravenous immunoglobulin alternately over the 10-day
period.
Flow cytometry and isolation of peripheral blood
mononuclear cells
Venous blood samples were collected into sterile EDTA-
containing tubes. Lymphocytes from peripheral blood
(100 μL; ~1 × 106 cells) were labelled with a 4-color
monoclonal antibody (mAb) panel: CYTO-STAT tetra-
Chrome CD45-FITC (clone: B3821F4A)/CD56-RD1
(clone: N901/NKH1)/CD19-ECD (clone: J3-119)/CD3-
PC5 (clone: UCHT1) + CD16-PE (clone: 3G8) and
CD45-FITC (clone: B3821F4A)/CD4-RD1 (clone: SFCI
12T4D11)/CD8-ECD (clone: SFCI21Thy2D3)/CD3 (clone:
UCHT1) (all Beckman Coulter, Brea, CA).
Extracellular staining of freshly prepared and isolated
peripheral blood mononuclear cells was performed with
anti-CD4-FITC (clone: RPA-T4) and anti-CD25-APC
(clone: BC96) antibodies prior to intracellular staining
with anti-FoxP3-PE (clone: PCH101). Tregs were stained
for intracellular FoxP3 with the Human Regulatory T Cell
Staining Kit (eBioscience, San Diego, CA, USA). An
appropriate isotype control mAb (rat IgG2a-PE, cocktail
of FITC and APC mouse IgG1) was used to establish the
settings for FoxP3+ Treg analysis.
Stained samples were analysed in the FC 500 flow
cytometer with CxP and Kaluza software (Beckman
Coulter). Flow cytometric analyses were performed with
at least 100 gated events. Lymphocyte subpopulations
were defined as follows: T lymphocytes, CD45+CD3+;
cytotoxic T lymphocytes, CD45+CD3+CD8+; and NK
cells, CD45+CD3−CD16+CD56+/-. Because basiliximab
may downregulate CD25 [16, 18] or interfere with some
anti-CD25 mAbs used for flow cytometry [19], Tregs
were defined as CD3+CD4+FoxP3+.
Gene expression analysis and RNA isolation
Peripheral blood was drawn directly into PAXgene tubes
(Qiagen, Hilden, Germany), frozen, and stored at -20 °C
until analysis. Whole-blood RNA was extracted with the
PAXgene Blood RNA Kit with DNAse I treatment (Qia-
gen). The purity and concentration of the RNA were
assessed in an ultraviolet–visible spectrophotometer
(NanoDrop 2000, Thermo Scientific). The RNA isolation
method routinely used in our laboratory was validated and
standardized on reference samples, to eliminate errors
and ensure the same standards across all measurements.
The quality of RNA samples obtained by the standard
Table 1 Demographic characteristics at the time of transplantation
Variable No-induction rATG Basiliximab P value
Number 19 24 17
Gender (M/F) 9/10 16/8 9/8 ns†
Recipient age (years)* 57 [27; 70] 54 [21; 78] 53 [25; 65] ns‡
Donor age (years)* 52 [16; 68] 46 [18; 74] 61 [21; 75] <0.05‡a
HLA MM* 3 [2; 6] 3 [1; 5] 3 [2; 5] ns‡
1st/2nd and 3rd KTx (n) 19/0 11/13§ 16/1 <0.0001†
PRA (%)* 4 [0; 22] 68 [0; 96] 6 [2; 63] <0.0001‡b
CNI (TAC/CsA) (n) 21/4 28/0 18/0 ns†
CIT (hours)* 16.2 [11.0; 20.7] 15.4 [7.7; 20.1] 17.2 [7.7; 21.0] ns‡
Dialysis time (years)* 2.0 [0.2; 5.7] 1.9 [0.5; 6.4] 2.0 [0.6; 4.9] ns‡
Cause of renal failure ns†
Primary GN 9 9 4
Hereditary diseases 2 5 4
Diabetic or ischemic nephropathy 6 2 7
TIN 2 1 1
ANCA vasculitis or lupus nephritis 0 4 0
Other causes 0 3 1
ANCA Anti-neutrophil cytoplasmic antibodies, CIT cold ischemic time, CNI calcineurin inhibitor, CsA cyclosporine A, GN glomerulonephritis, HLA MM HLA mismatch,
PRA historical panel-reactive antibodies, measured every 3 months before transplantation (the highest number in each patient was considered), TAC tacrolimus,
TIN tubulointerstitial nephritis, TxR renal transplantation
*Median [min; max]; †Chi square test P value; ‡Kruskal-Wallis test P value
Dunn's Multiple Comparison Test: aSignificant difference between the basiliximab group and the rATG group and a bsignificant difference between rATG and the
no-induction or basiliximab group
§2 patients had a 3rd transplantation
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isolation protocol was assessed with the Agilent 2100
Bioanalyzer (Agilent Technologies). An RNA integrity
number of 8–10 indicated high-quality RNA suitable for
further analysis.
Quantitative RT-PCR analysis
SuperScript™ II Reverse Transcriptase (Invitrogen, Carlsbad,
CA, USA) was used to synthesize cDNA from 2 μg of total
RNA isolated from blood samples. Seven genes were se-
lected on the basis of them being previously described as
being associated with rejection or tolerance: GZMB, PRF1,
CD247, FOXP3, TCAIM (C3orf23), MAN1A1, and TLR5.
Gene expression profiles of these seven genes were deter-
mined by quantitative real-time RT-PCR (qRT-PCR, 2-ΔΔCt
method), using HPRT1 and PGK1 as reference genes. The
cDNA from one control blood sample was used for calibra-
tion. The mRNA levels were quantified in triplicate for each
sample with a predesigned TaqMan® Gene Expression
Assay (Hs01554355_m1 for GZMB [granzyme B],
Hs00169473_m1 for PRF1 [perforin 1], Hs00167901_m1
for CD247, Hs00203958_m1 for FOXP3, Hs00603313_m1
for C3orf23 [TOAG or TCAIM], Hs00195458_m1 for
MAN1A1 [α-1,2-mannosidase], and Hs00152825_m1 for
TLR5) and the TaqMan® Fast Advanced Master Mix (Ap-
plied Biosystems). Quantitative RT-PCR amplification was
performed on an ABI Prism® 7900 H.T. Sequence Detection
system (Applied Biosystems). Relative quantification ana-
lysis was performed in 96-well plates, using the RQ Man-
ager 1.2. software for automated data analysis (Applied
Biosystems).
Statistical analyses
Characteristics of the rATG, basiliximab, and no-
induction groups were compared by the Kruskal-Wallis
test for continuous variables or the χ2 test for categorical
variables. Data were expressed as the median [min; max]
or as absolute numbers (n). A generalized linear mixed
model for repeated measures, adjusted for rejection,
donor/recipient age, and incidence of delayed graft func-
tion, was used for testing differences in the peripheral
blood gene expression and the absolute and relative num-
bers of lymphocyte subpopulations between groups. Due
to the non-normal distribution of data with long right
tails, the dependent variable was subjected to gamma
regression, with the data expressed as estimated marginal
means ± SEM. Calculations were done with SPSS 20 (IBM
Corporation, Somers, NY) and GraphPad Prism 5 (Graph-
Pad Software, La Jolla, CA). A two-sided P-value ≤ 0.05
was considered statistically significant.
Results
Patient survival, graft function, and rejection
One of the 60 patients died during the follow-up period
(day 223 after KTx) due to acute myocardial infarction.
There were no differences among the groups in terms of
delayed graft function (no-induction: 4/19, 21 %; rATG: 6/
24, 25 %; basiliximab: 7/17, 41 %) or the 12-month serum
creatinine, eGFR, and proteinuria results (Table 2). T cell-
mediated rejection occurred within 12 months after KTx
in 2/19 (10.5 %) of patients without induction and in 3/17
(17.6 %) of patients treated with basiliximab. Antibody-
mediated rejection developed in 4/24 (16.7 %) of patients
treated with rATG during follow-up. Borderline changes
occurred in 7/19 (36.8 %) of patients from no-induction
group, 4/24 (16.7 %) of patients from the rATG group,
and 7/17 (41.2 %) of patients from the basiliximab group.
T and NK cells
In the rATG group, depletion of T cells (CD3+), the
subpopulations (CD4+ T cells, CD8+ T cells, and CD4
+FoxP3+ Tregs), and NK cells were observed at 7 days
post-KTx, followed by a slow repopulation (Fig. 1a–d;
data for CD4+ not shown). The CD8+ T and NK cell
counts reached or exceeded their pre-KTx values at 12
month. The total cell counts for CD3+ T cells, CD4+ T
cells, and CD4+FoxP3+ Tregs, however, only reached 66,
34, and 68 % of the preKTx values respectively, at 12
month. The total CD3+ and CD8+ T cells reached sub-
stantially higher counts at 12 month as compared to the
pre-KTx values in the no-induction and basiliximab
groups (CD3+: 147 % and 155 %, CD8+: 170 % and 257 %,
respectively).
The absolute numbers of T cells, the subpopulations
(CD4+, CD8+, and CD4+FoxP3+ Tregs), and NK cells were
lower in the rATG group compared to the no-induction
and basiliximab groups during follow-up (all P < 0.001;
Fig. 1a–d; data for CD4+ not shown). CD8+ T cells were
decreased and the Treg cells were increased in the basi-
liximab group as compared to the no-induction group
(P < 0.05 and P < 0.01; Fig. 1b, d). In the basiliximab
group, the number of Tregs increased soon after KTx,
peaking on day 14 and then decreasing towards the
pre-KTx level (Fig. 1d).
In contrast to the absolute numbers, the frequency of
CD4+FoxP3+ Tregs among the CD4+ T cells was in-
creased compared to the pre-KTx levels at day 7 in the
rATG and basiliximab group. In rATG group the Treg
Table 2 Graft function at 12 months post transplantation






















eGFR estimated glomerular filtration rate, SCr serum creatinine
*Median [min; max]; ‡Kruskal-Wallis test P value
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frequency peaked at day 21 (to 303 % of the pre-KTx
value) and remained high (194 % of the pre-KTx value)
at the end of the follow-up period; in basiliximab group
CD4+FoxP3+ Treg frequencies decreased towards the
pre-KTx levels after day 7 and remained lower com-
pared to rATG group (P < 0.001; data for Treg frequen-
cies not shown). In the no-induction group, the Treg
frequencies were stable and lower than those of the
rATG and basiliximab group throughout the follow-up
period (P < 0.001 and P < 0.05, respectively; data for
Treg frequencies not shown).
Rejection-associated transcripts
In all groups, transcripts for CD247, GZMB, and PRF1
decreased on day 7, thereafter increasing slowly towards
their pre-KTx levels. The transcript levels decreased to
zero and were lowest among the groups (all P < 0.001;
Fig. 2a–c) in rATG group. Higher CD247 and GZMB
expression levels (both P < 0.01) were found in the basi-
liximab group compared to the no-induction group
(Fig. 2a, b).
MAN1A1 expression was highest (P < 0.001) in the
rATG group as compared to basiliximab and no-induction
groups (Fig. 2d). In all groups, the MAN1A1 expression
was increased on day 7 compared to the pre-KTx level.
MAN1A1 expression continued to increase in the rATG
group, whereas it stabilized in the other two groups on
day 14. In the rATG group, the MAN1A1 expression
peaked at day 21 and, thereafter, decreased towards its
pre-KTx value. Substantial differences in MAN1A1 ex-
pression were observed between the rATG group and
other groups from days 21 to 90 (Fig. 2d). The TLR5
mRNA expression was higher in the rATG group than in
the no-induction group (P < 0.05; Fig. 2e).
Tolerance-associated transcripts
Similar to the findings for CD247, GZMB, and PRF1, the
mRNA expression of FOXP3 was decreased in all groups
on day 7 compared to the pre-KTx level with the most
profound decrease and subsequent increase towards the
pre-KTx level in the rATG group. FOXP3 expression
was lowest in the rATG group; it was higher in the
basiliximab group than in the no-induction group (all
P < 0.001; Fig. 3a).
The trend of the mRNA expression ratio of FOXP3 to
MAN1A1 was similar to that of the FOXP3 expression;
the ratio decreased on day 7 in all groups, with the most
profound decrease and subsequent increase towards pre-
KTx levels being seen in the rATG group. The lowest
ratio was found in the rATG group (all P < 0.001; data
not shown). The TCAIM mRNA expression constantly
increased in all groups, with basiliximab- and rATG-
treated patients displaying the fastest and slowest
increases, respectively, among the groups (P < 0.01;
Fig. 3b).
Fig. 1 Effect of different inductive agents on the absolute numbers of T and NK cells in the peripheral blood of kidney transplant recipients
during a 1-year follow-up period. Absolute numbers of T cells (a), CD8+ T cells (b), NK cells (c), and CD4+FOXP3+ Tregs (d) measured by flow
cytometry in the peripheral blood from patients treated with rATG (squares on dashed line), basiliximab (triangles on dotted line), or without
induction (circles on solid line). Data are presented as estimated marginal means ± SEM
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Fig. 2 Effect of different inductive agents on expressions of rejection-associated transcripts expressed in the peripheral blood of kidney transplant
recipients during a 1-year follow-up period. Relative quantity (RQ) of CD247 (a), GZMB (b), PRF1 (c), MAN1A1 (d), or TLR5 (e) mRNA measured by
qRT-PCR in peripheral blood from patients treated with rATG (squares on dashed line), basiliximab (triangles on dotted line), or without induction
(circles on solid line). Data are presented as estimated marginal means ± SEM
Fig. 3 Effect of different inductive agents on tolerance-associated transcripts expressed in peripheral blood of kidney transplant recipients during
a 1-year follow-up period. Relative quantity (RQ) of FOXP3 (a) or TCAIM (b) measured by qRT-PCR in peripheral blood from patients treated with
rATG (squares on dashed line), basiliximab (triangles on dotted line), or without induction (circles on solid line). Data are presented as estimated
marginal means ± SEM
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Discussion
To the best of our knowledge, this is the first prospect-
ive trial that aimed to evaluate the effects of different
induction agents on molecular markers associated with
rejection or operational tolerance in kidney transplant
recipients. We analysed the relative quantity of seven
selected T cell-related transcripts, associated with oper-
ational tolerance or rejection, and lymphocyte subpopu-
lations in KTx patients treated with different induction
regimens. In our study the rATG induction therapy was
associated with profound decrease of T and NK cells, as
well as T cell transcripts that are exclusively expressed
by these cell types. In rATG group the transient upregu-
lation of MAN1A1 and TLR5 transcripts, previously
shown to be associated with chronic rejection [5], was
observed. Basiliximab induction resulted in a transient
increase in CD4+FoxP3+ Tregs, accompanied by the
highest peripheral expression levels of markers associ-
ated with operational tolerance (FOXP3 and TCAIM).
Many studies have documented the dose-dependent
depletional effect of rATG on T and NK cells [20–24].
However, little is known about transcript-level changes
due to rATG treatment. Simon et al. described the effect
of ATG induction therapy on expression of 10 immuno-
logically relevant genes in the early post-transplant
period and found decrease of GZMB and PRF1 expres-
sion [25]. We observed a profound drop in the relative
mRNA quantities of CD247, GZMB, PRF1, and FOXP3
early after transplantation in rATG group. These tran-
scripts are expressed exclusively by T and NK cells and
are present at different levels in rejecting or operation-
ally tolerant patients [2, 3, 7, 8]. The profound drop was
followed by a slow increase towards pre-KTx levels in
rATG patients, corresponding to the depletion and pro-
gressive repopulation of the aforementioned cell types.
Interestingly, in the early period after KTx, there was a
decrease in gene expression of CD247, GZMB, PRF1,
and FOXP3, followed by a return to pre-KTx levels, in
patients who were treated with basiliximab or without
induction. This finding can likely be explained by the
decreased NK cell counts and the effect of maintenance
therapy on gene expression. The calcineurin-dependent
mechanism of action involves the binding of CNIs to
their respective immunophilins. CNIs inhibit the tran-
scription of proinflammatory and T cell-recruiting cyto-
kines, such as interleukin (IL)-2 [26]. IL-2 regulates the
gene expression of perforin and granzyme [27]. It dir-
ectly promotes the transcription of FoxP3 [28, 29].
Moreover, IL-2 has been shown to augment TCR-ζ
(CD247) expression in chronic inflammation [30].
While the expressions of CD247, GZMB, PRF1, and
FOXP3 were downregulated, MAN1A1, TLR5 and TCAIM
transcripts were upregulated early after KTx in all groups.
These transcripts might be expressed preferentially by
other cell types than T cells which are more susceptible to
induction and maintenance immunosuppression. TCAIM,
MAN1A1 and TLR5 are expressed not only by T cells,
but also by macrophages/monocytes and dendritic cells
[6, 31–35]. The Indices of Tolerance Research Network
ranked TLR5 as one of the top-10 gene markers for dis-
tinguishing between drug-free operationally tolerant
and chronically rejecting kidney recipients. Specifically,
TLR5 was highly expressed in patients with chronic rejec-
tion, whereas it was downregulated in tolerant patients [5].
Similarly, increased expression of the other member of
toll-like receptors TLR4 was observed in kidney transplant
recipients with chronic rejection compared to operationally
tolerant patients [36]. After haematopoietic stem cell trans-
plantation, patients experiencing graft-versus-host disease
had increased peripheral TLR5 expression; adoptive
Treg therapy reduced this expression by preventing the
disease [34]. Although the differences in TLR5 expres-
sion in our study were statistically significant, the clin-
ical significance remains questionable.
TCAIM has been shown to be highly expressed during
the induction and maintenance of operational tolerance
to donor alloantigens in vivo, resulting in the acceptance
of kidney and heart allografts in rats and mice [6].
TCAIM expression was downregulated in the peripheral
blood and the graft before rejection. This downregula-
tion has been shown to occur in graft-infiltrating cells
and after T-cell activation in vitro [6, 37]. The TCAIM
protein is localized exclusively within mitochondria.
TCAIM-expressing murine T cells have been shown to
be more susceptible to apoptosis [38]. An increased
TCAIM mRNA level was described after administration
of regulatory macrophages to patients before living-
donor KTx [39]. In a rat KTx model, intragraft expres-
sion of TCAIM was dramatically reduced in untreated
rejecting recipients and in recipients who received an
adoptive transfer of memory T cells [40]. Recently, it was
shown that TCAIM inhibited spontaneous development
of memory and effector T cells [41]. Higher FOXP3 and
TCAIM expressions along with Treg numbers in basi-
liximab group may suggest a protective potential of
basiliximab. Here we showed that basiliximab induction
was associated with a transient increase in absolute
numbers of CD4+FoxP3+ Tregs which was in line with
findings of Bluestone et al. [42]. However the debate
has not been finished yet and there are also other ob-
servations [43, 44]. The rATG induction resulted in
long-lasting and profound depletion of absolute num-
bers of CD4+FoxP3+ Tregs that corresponded to de-
creased level of FOXP3 gene expression.
Conclusions
Induction immunosuppression with rATG was associated
with long-lasting suppression of T and NK cell-associated
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genes, and with the upregulation of markers associated
with rejection, MAN1A1 and TLR5, within the first month
after KTx. In contrast, basiliximab induction resulted in a
fast increase in CD4+FoxP3+ Tregs and expression of
some markers associated with operational tolerance.
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